Abstract 4813: Demographic, treatment, and survival patterns in Hispanic vs. non-Hispanic patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia: A national retrospective analysis from the National Cancer Database
Authors: Fierro Maria Elena , Latiolais Heidi , Liu Qianquian , Michalek Joel , Duque Adolfo Enrique Diaz 
Published: March 2024

Background: Lymphoplasmacytic lymphoma (LPL) is a rare type of non-Hodgkin B cell lymphoma. Waldenstrom macroglobulinemia (WM) is a form of LPL that presents with overproduction of IgM monoclonal protein. The understanding and treatment of LPL/WM has improved. However, few studies analyze LPL/WM in Hispanic (HI) patients specifically. This study aims to evaluate demographics, treatment, and survival patterns in HI vs. Non-Hispanic (NH) patients with LPL/WM.

Methods: Data were analyzed on LPL/WM patients in the US reported to the NCDB from 2004-2019. Demographic and treatment characteristics were compared between ethnic groups. Kaplan-Meier and Cox regression analyses were used to compare overall survival (OS) between HI and NH. Multivariate analysis and propensity score matching were performed with adjustment for age, stage, co-morbidity score, insurance status, type of facility and great circle distance (GCD).

Results: 17,915 patients were identified. 92% were NH, 3% were HI. Most patients were male in both NH and HI (p = 0.120). The median age at diagnosis for HI was 68 vs. 71 for NH (p &lt; 0.001). Most HI and NH were white (87% HI, 91% NH p &lt; 0.001). More HI were uninsured (8% HI, 1% NH p &lt; 0.001) and were less likely to have government sponsored insurance (60% HI, 66% NH p &lt; 0.001). Regarding income, most NH (42%) were in the $63,000+ bracket while most HI were in the $48,000-$62,999 bracket. Regarding education, reported in percent quartiles with no high school degree, most HI (41%) were in the &gt; 21% bracket while most NH (35%) were in the 7-12.9% bracket (p &lt; 0.001). Most HI (43%) were treated at academic/research programs; most NH were treated at comprehensive community cancer programs (38.4%, p &lt; 0.001). Regarding comorbidities score, 9% of HI scored ≥ 2 vs 8% of NH (p 0.029). Regarding GCD, the median distance in miles between the patient’s residence and the hospital that reported the case, HI lived at a median of 6.7 miles vs 9 miles for NH (p &lt; 0.001). Regarding treatment, 68% of HI were given treatment vs. 62% of NH (p &lt; 0.001). There was no difference in mortality between HI vs. NH (30 day mortality p = 0.322; 90 day mortality p = 0.217). On survival analysis, the survival probability at 2, 5 and 10 years of HI vs NH were 81% vs 83%, 69% vs 68%, and 52% vs 46%, respectively. The median survival time (MS) was 10.6 years for HI vs 9 years for NH. There was no OS difference between HI vs. NH (p = 0.47). On multivariate analysis, there were no independent variables associated with better or worse OS. The propensity matched analysis showed no MS difference between HI vs NH (8.96 y vs. 8.74 y).

Conclusion: We identified ethnic differences in age, race, insurance, education, income, location of treatment, GCD, staging, and treatment patterns. However, there was no statistically significant ethnic difference in MS or OS.

Citation Format: Maria Elena Fierro, Heidi Latiolais, Qianquian Liu, Joel Michalek, Adolfo Enrique Diaz Duque. Demographic, treatment, and survival patterns in Hispanic vs. non-Hispanic patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia: A national retrospective analysis from the National Cancer Database [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4813.